Promising developments at the 16th International Conference on Alzheimer’s and Parkinson’s Diseases
The 16th AD/PD™ 2023 opened on March 28th in the Swedish Exhibition & Congress Centre with a welcome address by Her Majesty Queen Silvia of Sweden, who highlighted the importance of research in Alzheimer’s and Parkinson’s diseases and expressed her gratitude for the efforts of the scientific community to find effective treatments for these debilitating conditions.
This premier scientific meeting concluded on the 1st of April after five empowering days of presentations, workshops, and networking sessions. AD/PD™ 2023 brought together 4,120 participants from around the world – 3,289 onsite and 831 online – including leading scientists, clinicians, and industry representatives, to discuss the latest advances in Alzheimer’s, Parkinson’s, and related diseases.
AD/PD™ 2023 featured 1,019 talks (673 onsite and 346 by online participants), 112 symposia, eight industry symposia, seven plenary presentations and six forum discussions. The lectures covered a wide range of topics pertaining to Alzheimer’s, Parkinson’s, and related neurodegenerative diseases, encompassing genetics, biomarkers, cutting-edge technologies, clinical trials, and therapeutics.
“We are thrilled with the outcome of this year’s AD/PD™ Conference”, said Professor Abraham Fisher, President of AD/PD™. He added: “The Conference has provided a unique platform for sharing new research findings and promoting collaborations among scientists and clinicians worldwide. We are confident that the insights and innovations presented at this Conference will accelerate progress towards finding effective treatments for Alzheimer’s and Parkinson’s diseases.”
The next AD/PD™ Conference will take place on March 5 – 9, 2024 in Lisbon, Portugal.
The International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) is a groundbreaking series of annual Conferences initiated by the Professional Conference Organiser (PCO) Kenes Group, that bring together leading scientists, clinicians, and industry experts to discuss the latest advances and research in Alzheimer’s and Parkinson’s diseases, and related neurological disorders.
Learn more about the conference here.